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ThestudyaimedtodeterminetheeﬀectoftheactivatedproteinConthecourseofsystemicinﬂammationintheAPCAP(activated
protein C in acute pancreatitis) trial where we randomized 32 patients with severe acute pancreatitis to receive either recombinant
activated protein C (drotrecogin alfa activated) (n = 16)orplacebo(n = 16)for96hours.Inthepresentstudy,wepresentthetime
course of the patients’ plasma or serum levels of soluble markers (IL-8, IL-6, IL-10, IL-1ra, sE-selectin, PCT) and monocyte and
neutrophil cell surface (CD11b, CD14, CD62L, HLA-DR) markers of systemic inﬂammatory response during the ﬁrst 14 days after
therandomization.TheresultsoftheinterventionandplacebogroupswerecomparableshowingthatrecombinantAPCtreatment
didnotalterthecourseofsystemicinﬂammationinsevereacutepancreatitis.Ourﬁndingisinaccordancewiththeclinicalﬁndings
in the APCAP trial indicating that the intervention did not aﬀect evolution of multiple organ dysfunctions.
1.Introduction
Acute pancreatitis (AP), a common cause of abdominal pain,
is usually a mild, self-limited disease. However 25% of the
patients suﬀer from severe AP (SAP) [1], and 20% of SAP
patients die, [2], mostly due to the development of multiple
organ dysfunction [3]. Systemic inﬂammation, typical of AP,
is considered to contribute to the development of organ
dysfunction. It is characterized by (i) an increase in circula-
ting levels of proinﬂammatory cytokines [4, 5], anti-inﬂam-
matory cytokines [6–9], and soluble E-selectin (sE-selectin)
[10–12], a marker of activation of the vascular endothelium,
(ii) occurrence of activated phagocytes in the circulation [13,
14], and (iii) a decrease in HLA-DR expression on blood
monocytes [9, 13, 15, 16], denoting the development of im-
mune suppression.
Activated protein C (APC) is a plasma serine protease
with eﬀects on coagulation, apoptosis, and inﬂammation
[17]. APC acts as an endogenous anticoagulant that pro-
motes ﬁbrinolysis and inhibits thrombosis. Protein C, an in-
active precursor, is converted to activate protein C by throm-
bin-thrombomodulin complex on endothelium [18]. This
processisacceleratedinthepresenceofendothelialPCrecep-
tor (EPCR) [19]. APC inactivates the procoagulation factor
Va and VIIIa shutting down the coagulation pathway. APC
also inactivates plasminogen activator inhibitor, which re-
sults in increased ﬁbrinolysis [18].
APC also has cytoprotective eﬀects such as anti-inﬂam-
matory, antiapoptotic, and endothelial barrier protection
eﬀects [20].
Proinﬂammatory cytokines upregulate thrombin forma-
tion and downregulate the host’s antithrombotic mecha-
nisms, in particular the protein C (PC) pathway reviewed in
[21]. Deﬁciency of PC and decreased generation of activated
PC (APC), the major endogenous anticoagulant in man,
associate with the development of organ dysfunction in AP2 International Journal of Inﬂammation
[22]. In patients with sepsis human recombinant APC short-
ened the duration of respiratory dysfunction and accelerated
the reversal of shock [23]. We studied in a randomized trial
patients with severe AP and found no diﬀerences in the evo-
lution of multiorgan dysfunction between APC and placebo
groups [24]. However, the eﬀects of APC on inﬂammatory
markers in patients with SAP have not been studied in a
randomized controlled trial previously.
Accordingly, we aimed to determine the eﬀects of the
APC intervention on plasma levels of proinﬂammatory (IL-
8), pro-/anti-inﬂammatory (IL-6) and anti-inﬂammatory
(IL-10, IL-1ra) [25] cytokines and sE-selectin, on activation
markers of blood monocytes (CD14, CD11b, CD62L) and
neutrophils (CD11b, CD62L), on levels of monocyte cell-
surfaceexpressionofHLA-DR,amarkerofimmunesuppres-
sion, and on serum levels of procalcitonin (PCT), a marker
of systemic inﬂammation used in clinical decision making.
2.SubjectsandMethods
2.1. Patients and Healthy Subjects. We previously conducted
a randomized study of APC in SAP patients [24]. In brief,
this prospective randomized double-blind study included
analysis of 32 patients with SAP in the tertiary care unit at
the Helsinki University Central Hospital between June 2003
and August 2007. The inclusion criteria were (1) admitted
to hospital <96h from the onset of pain, (2) a 3-fold in-
crease in serum amylase (IU/L) over normal upper range
or/and veriﬁcation of SAP in computer tomography, (3) at
least one organ dysfunction (OD) deﬁned as the Sequential
Organ Failure Assessment (SOFA) of at least 3 of 4, and (4)
<48 hours from the ﬁrst OD. Patients were randomized to
receive either APC (drotrecogin alfa activated) (N = 16) or
0.9% physiologic saline as placebo (N = 16). APC was admi-
nistrated for 96 hours with a dose of 24μg/kg/hour.
We obtained reference blood samples for the analyses
of cell surface markers by ﬂow cytometry from 65 healthy
volunteers (137 samples) from the hospital and laboratory
staﬀ without medication and with no signs of infection. To
monitor the level of ﬂuorescence intensity, a blood sample
from a healthy volunteer was studied according to the study
protocol once a week. There were 58 women and 7 men in
the reference group. In case of repeated sampling, mean of
the data was used.
The study protocol was approved by the ethics commit-
tees of the Helsinki University Central Hospital. Informed
consent was obtained from all patients or their next of kin.
The study protocol was registered in ClinicalTrials.gov (NC-
T01017107).
2.2. Blood Samples. When a patient fulﬁlled the inclusion
criteria we collected peripheral blood samples for determi-
nation of cell markers of inﬂammation by venipuncture for
the ﬁrst time. Then the patients were randomized. After that
follow-up samples were collected in the morning of the
third, ﬁfth, seventh, and 14th day. Blood samples for ﬂow
cytometry and for plasma measurements were anticoagu-
lated with pyrogen-free acid-citrate dextrose (ACD). Blood
samples were immediately cooled in an ice-cold water bath
a n dk e p ta t0 ◦C until stained for ﬂow cytometry. The plasma
was separated by centrifugation at +4◦Ca n ds t o r e da t
−70◦CuntilconcentrationsofcytokinesandsE-selectinwere
determined. Blood samples for determination of serum PCT
were collected concurrently.
2.3. Analysis of Soluble Markers. The concentrations of IL-6,
IL-8, IL-10, IL-1Ra, and E-selectin in plasma samples were
determined by enzyme immunoassay (EIA) by using com-
mercial reagents (IL-6 and IL-10: PeliPair ELISA, Sanquin,
Amsterdam, theNetherlands; IL-8: Opt EIA, BD Biosciences,
Erembodegem, Belgium; IL-1Ra: Duo Set ELISA, R&D Sys-
tems Europe Ltd, Abindgon, UK; E-Selectin: ELISA, HyCult
Biotechnology, Uden, The Netherlands). The detection lim-
its and intra-assay and interassay coeﬃcients of variation
(CV%) were as follows: IL-6: 0.3pg/mL, 3.6% and 5.4%;
IL-8: 1.6pg/mL, 3.5%, 3.4%; IL-10: 0.3pg/mL, 3.7%, 5.9%;
IL-1Ra: 10pg/mL, 4.2%, 5.2%; E-selectin 20.5pg/mL, 3.5%,
6.9%.
Procalcitonin (PCT) was measured using ADVIA
Centaur XP immunoassay system with ADVIA Centaur
BRAHMS PCT assay. Assay is a sandwich chemiluminescent
immunoassay using monoclonal antibody to ﬂuorescein
covalently linked to paramagnetic particles and two antibod-
ies to procalcitonin labelled with ﬂuorescein. According to
the manufacturer, the within-run precision of the method is
4.3%, 1.5%, and 1.5% for PCT at 0.2, 0.97, and 65.9μg/L,
respectively. The between-run precision is 8.5%, 2.1%, and
7.2%fortherespectiveconcentrations.Thelimitofdetection
for the assay is 0.04μg/L and dilution point 75μg/L.
2.4. Analysis of Cell Surface Markers
Monoclonal Antibodies and Flow Cytometry. Monocyte exp-
ression of CD14, CD11b, CD62L and HLA-DR and neu-
trophil expression of CD62L and CD11b were determined
using whole blood ﬂow cytometry, as described previously
[9, 13]. Monoclonal antibodies (mAbs) were as follows: phy-
coerythrin (PE) and ﬂuorescein isothiocyanate (FITC) con-
jugates of anti-CD14 mAb (IgG2b, clone MFP9), PE con-
jugates of anti-HLA-DR mAb (IgG2a, clone L243), anti
CD11b mAb (IgG2a, clone D12) and control mouse IgG2a,
mAb, and FITC conjugate of anti-CD62L mAb (IgG2a, clone
SK11). All reagents were purchased from Becton Dickinson
(San Jose, CA, USA). Staining of aliquots of the whole blood
sample at 0◦Cf o rﬂ o wc y t o m e t r yw a sc a r r i e do u ta sd e s -
cribed previously [9, 13]. Data acquisition and analyses were
done by a FACSCalibur ﬂow cytometer and Cell Quest soft-
ware (BD Sciences, San Jose, CA). Neutrophils were iden-
tiﬁed by the light scattering properties and monocytes by
the clonal marker CD14. Monocyte HLA-DR expression was
determined as the proportion of HLA-DR positive mono-
cytes, as described earlier [13]. Fluorescence intensity is pre-
sented as relative ﬂuorescence units (RFUs).
2.5. Statistical Analysis. The primary end point of the ran-
domized study was the change in SOFA score. The sampleInternational Journal of Inﬂammation 3
Table 1: Characteristics of patients.
Activated protein C Placebo
No. of patients 16 16
Male/female 16/0 15/1
Etiology of SAP
-Alcohol/biliary 16/0 15/1
Age (years) 44 (34–36) 47 (19–59)
SOFA score on
admission 8.0 (3–13) 8.5 (3–15)
ICU stay (days) 10.0 (2–43) 11.0 (0–31)
∗Values are median (range).
size for the study was determined according to the primary
end point: there would be three-point diﬀerence in change of
SOFA score between the groups (with P<0.05 and a power
of 80%) [24]. Values are given as medians and ranges. Com-
parisons of marker levels between the two groups (the APC
group and the placebo group) were performed by the Mann-
Whitney U-test. In case of repeated sampling from the
healthy volunteers mean data was used to get one value for
each person and after that median was used. The Wilcoxon
signed-rank test was used in comparisons of repeated mea-
surements. A diﬀerence with a P-value of less than 0.05 was
considered to be statistically signiﬁcant. Statistical analysis
was performed using SPSS19.0 statistical software (Chicago,
Illinois).
3. Results
3.1. Patients. Characteristics of the 32 SAP patients are given
in Table 1. All except one of the patients were admitted to the
ICU. The time before patients were admitted to the ICU was
1,0 days (0–3 days) in APC group and 2,0 (1-2 days) in the
placebo group (P = 0.642). In the APC group there were two
nonsurvivors: one after receiving 13 hours of APC infusion
and the other one having a laparotomy after 41 hours of APC
infusion.
3.2. Soluble Markers. Plasma concentrations of proinﬂam-
matorycytokineIL-8ofallpatientsdecreasedduringtheﬁrst
ﬁve days after the admission to hospital (day 0: 264pg/mL
versusday5:110pg/mL,P = 0.001).TheAPCtreatmenthad
no signiﬁcant eﬀe c to nt h ec h a n g e si nI L - 8c o n c e n t r a t i o n s
during the follow-up period (Table 2).
Plasma concentrations of pro-/anti-inﬂammatory cyto-
kine IL-6 (Figure 1), anti-inﬂammatory cytokines IL-10 and
IL-1Ra of all patients decreased during the ﬁrst ﬁve days of
the follow-up time (IL-6 day 0: 670pg/mL versus day 5:
215pg/mL, P = 0.001; IL-10 day 0: 12.7pg/mL versus day 5:
11.3pg/mL, P = 0.001; IL-1Ra day 0: 2890pg/mL versus day
5: 1250pg/mL, P = 0.007). The APC treatment did not have
any signiﬁcant eﬀect on the changes in IL-6, IL-10, and IL-
1Ra concentrations during the ﬁrst ﬁve or 14 days of follow-
up time (Table 2).
PlasmaconcentrationsofsolubleE-selectinofallpatients
decreased along the course of the disease (day 0: 45.5ng/mL
Days from randomization
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Figure 1: The changes in concentrations of IL-6 during the follow-
up time. The APC did not have signiﬁcant eﬀect on the changes
(P = 0.288). Box-Whisker plots show median, interquartile range
(box) and highest and lowest values. Outliers (circles) and extreme
values (asterisks) are shown separately.
versus day 5: 38.2ng/mL, P = 0.031), but the APC treat-
ment did not have any signiﬁcant eﬀect on the changes in
concentrations of sE-selectin (Table 2).
There were no signiﬁcant changes in serum concentra-
tions of procalcitonin of all patients during the ﬁrst ﬁve days
(day 0: 0.97ng/mL versus day 5: 0.66ng/mL, P = 0.487), and
administration of APC did not alter the changes in PCT con-
centrations (Table 2).
3.3. Cell Surface Markers. A sam a r k e ro fi m m u n es u p p r e s -
sion monocyte HLA-DR expression of all patients was not
altered signiﬁcantly during the ﬁrst ﬁve days of follow-up
period (day 0: 54% versus day 5: 58%, P = 0.316). Neither
had the APC infusion any eﬀect on the HLA-DR expression
(Table 3).
ThecellsurfaceexpressionsofCD11b,CD14,andCD62L
were measured as markers of activation of monocytes. The
cell surface expression of CD11b, CD14, and CD62L on
monocytes of all patients was downregulated during the ﬁrst
ﬁve days (MoCD11b day 0: 291RFU versus day 5: 200RFU,
P = 0.001; MoCD14 day 0: 168RFU versus day 5: 150RFU,
P = 0.028; MoCD62L day 0: 217RFU versus day 5: 135RFU,
P = 0.001). The expression of CD11b, CD14, and CD62L
didnotdiﬀersigniﬁcantlybetweentheplaceboandtheAPC-
treatment group (Table 3).4 International Journal of Inﬂammation
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Figure 2: The changes in expression of CD62 on neutrophils during the follow-up time. The APC did not have signiﬁcant eﬀect on the
changes (P = 0.251). Box-Whisker plots show median, interquartile range (box) and highest and lowest values. Outliers (circles) are shown
separately.
The expressions of CD11b and CD62L were measured
as markers of neutrophil activation. The expressions of
CD11b and CD62L (Figure 2) of all patients were both
downregulated during the ﬁrst ﬁve days of follow-up period
(PMNCD11b day 0: 325RFU versus day 5: 259RFU, P =
0.001; neutrCD62L day 0: 146RFU versus day 5: 81RFU,
P = 0.001). The APC treatment did not have any eﬀect on
the changes in CD11b or CD62L expression on PMN cells
between days 0 and 5 (Table 3).
4. Discussion
The results show that recombinant APC (drotrecogin alfa
activated) treatment of patients with SAP did not alter the
course of systemic inﬂammation, as determined using solu-
ble and cellular markers of systemic inﬂammatory response.
This is in accordance with the clinical ﬁndings of these
patients, which indicated that SOFA score changes, organ-
failure-free days, ICU or hospital stay time, ventilator-free
days, renal replacement therapy-free days, vasopressor-free
days, or days alive outside hospital (in 60 days) were com-
parable between APC and placebo groups [24]. The overall
decreasing tendency of cytokines during the followup resem-
bles earlier results, which show that both pro- and anti-
inﬂammatory bursts are an early phenomenon in severe AP
[15].
Several in vitro and animal studies show that APC has
an anti-inﬂammatory activity. Administration of APC has
been shown to downregulate the expression of inﬂammatory
cytokines and chemokines. APC blocks cytokine produc-
tion from Th2 lymphocytes [26]. APC has been shown to
reduce production of endotoxemia-induced proinﬂamma-
tory cytokines (IL-6, IL-8, IL-1beta, and TNF alfa) [27]. In
vitro the production of IL-8 from monocytes is inhibited by
APC (LPS-stimulated THP-1 cells) [28]. In vitro APC has
been shown to inhibit chemotaxis and IL-6 release by human
neutrophils [29]. APC inhibits TNF-alpha production by
blocking nuclear factor (NF) kB transcription factor in
monocytes [30]. APC has been shown to upregulate anti-
inﬂammatory mediators, like IL-10 in blood monocytes in
patients with severe sepsis [31]. APC can also block leuko-
cyte traﬃcking by decreasing the expression of adhesion
molecules (ICAM-1, E-selectin, and VCAM-1) on the endo-
thelium [32–35].
Several clinical trials have been established to evaluate
the APC treatment in sepsis patients. In the PROWESS trial
they found that recombinant human activated protein C
(drotrecogin alfa) reduced mortality in patients with severe
sepsis [36]. In this randomized multicentre trial they found
decreases in D-dimer levels and IL-6 levels in patients’
plasma that has been taken as evidence of anti-inﬂammatory
action of APC [23]. HLA-DR expression, as marker of im-
munosuppression, has been shown to correlate with PC and
APC levels in SAP [22]. Preliminary, still unpublished results
from the PROWESS-SHOCK trial indicated that APC did
nothaveabeneﬁcialeﬀecton28-daysurvivalinpatientswith
septic shock.International Journal of Inﬂammation 7
No previous randomized trial has scrutinized the eﬀect
of APC in SAP patients, nor is there such evidence of APC’s
eﬀect on inﬂammation in SAP. The present study of phlogis-
tic markers supports the view that APC treatment does not
aﬀect either the course of systemic inﬂammation in agree-
ment with no detected eﬀe c to no r g a nd y s f u n c t i o n[ 24].
Limitations of the study. The sample size for the study
(16+16) was determined according to the primary end point
and not for comparing systemic inﬂammatory response bet-
ween the groups. In addition the number of follow-up sam-
ples/patients was decreased at day ﬁve (12+14) and at day 14
(11+10);thereforeitisnotpossibletoexcludeatypeIIerror.
5. Conclusion
TherecombinantAPC(drotrecoginalfaactivated)treatment
of patients with SAP did not alter the course of systemic in-
ﬂammation, as determined using soluble and cellular mark-
ers of systemic inﬂammation.
Abbreviation
APCAP: Activated protein C in acute pancreatitis
AP: Acute pancreatitis
SAP: Severe acute pancreatitis
PC: Protein C
APC: Activated protein C
PCT: Procalcitonin
OD: Organ dysfunction
SOFA: Sequential organ failure assessment
EIA: Enzyme immuno assays
RFU: Relative ﬂuorescence units
ICU: Intensive care unit
PROWESS: Recombinant Human Activated Protein C
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